Group 1 - Rise Gold Corp. has granted a total of 1,445,469 stock options to directors, officers, and consultants under its Long Term Incentive Plan, with an exercise price of US$0.25 (CAD$0.35) per share until October 30, 2030 [1] - The Company has also granted 1,365,854 deferred share units (DSUs) to certain directors and officers, with each DSU entitling the holder to receive one Common Share upon cessation of being an Eligible Person [2] - Rise Gold is an exploration-stage mining company incorporated in Nevada, USA, with its principal asset being the historic Idaho-Maryland Gold Mine located in Nevada County, California [3]

Core Viewpoint - Marvel Biosciences Corp. has awarded 142,987 deferred share units (DSUs) to two directors as a form of compensation instead of cash payment, with the DSUs set to vest on July 31, 2026 [1][2]. Group 1: Company Overview - Marvel Biosciences Corp. is a Calgary-based pre-clinical stage pharmaceutical development biotechnology company [3]. - The company is developing MB-204, a novel fluorinated derivative of the anti-Parkinson's drug Istradefylline, which is the only clinically approved adenosine A2a antagonist [3]. - There is growing scientific evidence suggesting that drugs blocking the adenosine A2a receptor, like MB-204, may be effective in treating various neurological diseases, including autism, depression, and Alzheimer's Disease [3]. - The company is also exploring the potential of MB-204 in addressing neurodevelopmental disorders such as Rett Syndrome and Fragile X Syndrome to broaden its therapeutic applications [3]. Group 2: Financial Details - The deemed value of the awarded DSUs is calculated at $0.16 per share based on the volume-weighted average price (VWAP) of the company's common shares on the TSX Venture Exchange as of July 31, 2025 [2]. - Vested DSUs will be settled upon the directors' separation from the company and will expire 365 days after such separation [2].